Reliance Life Sciences
The Reliance Group is India s largest private sector enterprise, with annual revenues of US$ 66.8 billion. The Group s activities span oil and gas exploration and production, petroleum refining, petrochemicals, polyester, plastics, organized retailing and telecom. The Group s flagship company Reliance Industries Limited is the largest private sector company and a Fortune Global 500 company.
Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. RLS was established to develop business opportunities in medical biotechnology with key initiatives in biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical research and molecular diagnostics.
From a domain perspective, these opportunities cover:
Biopharmaceuticals (Plasma Proteins, Biosimilars (Recombinant Proteins, Monoclonal Antibodies) and Novel Proteins)
Pharmaceuticals (Oncology, Steroid, Hormone and Peptide – Active Pharmaceutical Ingredients and Formulations )
Clinical Research Services (Pre-clinical animal studies, Bioavailability and Bioequivalence studies, Phase 1 studies, Phase 2 to 4 studies, QTc studies, Mass balance/Micro dosing studies, Clinical Data Management, Biostatistics, Clinical Trial Supplies Management, Medical Writing, Pharmacovigliance, Regulatory Services and Quality Assurance)
Regenerative Medicine (Stem Cell therapies, Tissue Engineered products, Stem Cell enriched Repository Services, Assisted Reproduction and Fetal Medicine)
Molecular Medicine (DNA/RNA-based diagnostics, Molecular Genetics, Predictive Diagnostics, Histopathology, Cytopathology, Flow Cytometry based diagnosis, Pharmacogenomics)
From an integration perspective, these opportunities encompass Repositories, Research, Process Development, Pre-clinical Studies, Human Clinical Trials, Commercial-scale Manufacture and Marketing, all of which are carried out in-house
Reliance GeneMedix plc, a UK-based subsidiary of Reliance Life Sciences with a manufacturing facility in Ireland, is developing biosimilars for the European market.
Reliance Institute of Life Sciences is a not-for-profit organisation, focusing on competency development in Biotechnology, not only for Reliance Life Sciences but also for the industry. The institute offers a wide range of competency development programs and diploma programs in Biotherapeutics and Clinical Research.
Reliance Life Sciences initiative is one of the most diverse and integrated biotechnology initiatives being developed anywhere in the world.
Consistent with the diversity and depth of its initiatives, Reliance Life Sciences has a professional team comprising substantially of Ph. Ds, M.Ds, Engineers and Post Graduates in Science. The average age of the Reliance Life Sciences team is 33 years. 26% of the employees are women.
RLS operates state-of-the-art facilities in life sciences domain. The flagship facility is Dhirubhai Ambani Life Sciences Centre (DALC) in Navi Mumbai. Spread over 20 acres, DALC is among the most diverse and integrated life sciences campuses in the world. Its diversity stems from the wide spectrum of areas of research and development undertaken and its integration comes from repository, laboratory research, pre-clinical research, clinical research and manufacturing facilities; all located in the same campus. A second facility is in Bangalore, for clinical pharmacology and clinical data management.
Today RLS is a fully-integrated life sciences industry player with in-house capabilities in research, pre-clinical and clinical development, process development, commercial-scale manufacturing, marketing and local sales organization. The company employs about 800 people, many of whom have PhDs or post-graduate degrees.